Brief: Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint
19/03/2025 12:24
March 19 (Reuters) - Roivant Sciences Ltd ROIV.O: ROIVANT ANNOUNCES POSITIVE RESULTS FOR BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) STUDIES ROIVANT SCIENCES LTD - PHASE 3 MG STUDY MEETS PRIMARY ENDPOINT WITH 5.6 POINT IMPROVEMENT Source text: ID:nGNX81VgfG Further company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million